Shares of Tandem Diabetes Care Inc. (NASDAQ:TNDM) traded up 3.3% on Wednesday . The company traded as high as $7.24 and last traded at $7.23, with a volume of 207,395 shares traded. The stock had previously closed at $7.00.

A number of analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a research report on Wednesday, July 6th. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of Tandem Diabetes Care in a research report on Friday, July 29th. Finally, Sterne Agee CRT reissued a “neutral” rating on shares of Tandem Diabetes Care in a research report on Monday, May 16th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. Tandem Diabetes Care presently has a consensus rating of “Hold” and an average target price of $14.21.

The company has a 50-day moving average price of $7.06 and a 200-day moving average price of $7.96. The firm’s market capitalization is $216.13 million.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.60) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.05. The firm earned $23 million during the quarter, compared to the consensus estimate of $23.08 million. The company’s quarterly revenue was up 46.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.65) EPS. On average, analysts forecast that Tandem Diabetes Care Inc. will post ($2.14) EPS for the current year.

In related news, EVP John F. Sheridan sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $6.52, for a total value of $97,800.00. Following the completion of the sale, the executive vice president now owns 22,763 shares of the company’s stock, valued at approximately $148,414.76. The sale was disclosed in a document filed with the SEC, which is available at this link.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.